The Association Between STX1B Polymorphisms and Treatment Response in Patients With Epilepsy

Background: Epilepsy is a debilitating brain disease with complex inheritance and frequent treatment resistance. However, the role of STX1B single nucleotide polymorphisms (SNPs) in epilepsy treatment remains unknown. Objective: This study aimed to explore the genetic association of STX1B SNPs with...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 701575
Main Authors Wang, Shitao, Zhou, Liang, He, Chenglu, Wang, Dan, Cai, Xuemei, Yu, Yanying, Chen, Liling, Lu, Di, Bian, Ligong, Du, Sunbing, Wu, Qian, Han, Yanbing
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 09.07.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background: Epilepsy is a debilitating brain disease with complex inheritance and frequent treatment resistance. However, the role of STX1B single nucleotide polymorphisms (SNPs) in epilepsy treatment remains unknown. Objective: This study aimed to explore the genetic association of STX1B SNPs with treatment response in patients with epilepsy in a Han Chinese population. Methods: We first examined the associations between STX1B SNPs and epilepsy in 1000 Han Chinese and the associations between STX1B SNPs and drug-resistant epilepsy in 450 subjects. Expression quantitative trait loci analysis was then conducted using 16 drug-resistant epileptic brain tissue samples and results from the BrainCloud database ( http://eqtl.brainseq.org ). Results: The allelic frequencies of rs140820592 were different between the epilepsy and control groups ( p = 0.002) after Bonferroni correction. The rs140820592 was associated with significantly lower epilepsy risk among 1,000 subjects in the dominant model after adjusting for gender and age and Bonferroni correction (OR = 0.542, 95%CI = 0.358–0.819, p = 0.004). The rs140820592 also conferred significantly lower risk of drug-resistant epilepsy among 450 subjects using the same dominant model after adjusting for gender and age and Bonferroni correction (OR = 0.260, 95%CI = 0.103–0.653, p = 0.004). Expression quantitative trait loci analysis revealed that rs140820592 was associated with STX1B expression level in drug-resistant epileptic brain tissues ( p = 0.012), and this result was further verified in the BrainCloud database ( http://eqtl.brainseq.org ) ( p = 2.3214 × 10 –5 ). Conclusion: The STX1B rs140820592 may influence the risks of epilepsy and drug-resistant epilepsy by regulating STX1B expression in brain tissues.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of the journal Frontiers in Pharmacology
Stanley Hooker, City of Hope National Medical Center, United States
Reviewed by: Yanfei Zhang, Geisinger Health System, United States
Edited by: Youssef Daali, Geneva University Hospitals (HUG), Switzerland
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.701575